UPDATE: Mersana Therapeutics stock leaps 4.7% after FDA lifts clinical hold on cancer therapy trial [MarketWatch]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: MarketWatch
UPDATE: Mersana Therapeutics stock leaps 4.7% after FDA lifts clinical hold on cancer therapy trial Mersana Therapeutics Inc. MRSN, +1.77% said Monday the U.S. Food and Drug Administration has lifted a partial clinical hold on its phase I trial of its cancer treatment XMT-1522. The hold was imposed in July after a patient enrolled in the trial died, sending the stock down sharply. XMT-1522 is the most advanced therapy in Mersana's pipeline. The trial, which is testing the drug in individuals with breast, gastric and non-small cell lung cancers, will resume with four-weekly dosing. "Mersana and the FDA reached alignment on changes to the protocol, including increased monitoring as well as the exclusion of patients with advanced hepatic impairment," the company said in a statement. It will apply the same protocol to its other therapy XMT-1536 trial, which was not subject to the clinical hold but is also in early-stage clinical trials. Shares are down 12.5% in 2018 through Friday, whi
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.MarketBeat
- AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]Seeking Alpha
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
MRSN
Earnings
- 2/28/24 - Beat
MRSN
Sec Filings
- 4/3/24 - Form 4
- 2/28/24 - Form 8-K
- 2/28/24 - Form 424B5
- MRSN's page on the SEC website